Effectively immediately, the federal requirement to have a waiver (DATA X-waiver/Notice of Intent) to prescribe medications for the treatment of opioid use disorder (OUD), such as buprenorphine is NO longer required, and prescribers are able to, and encouraged by the Substance Abuse and Mental Health Services Administration (SAMHSA), to prescribe buprenorphine in their practices as permitted by applicable state law.
Below is information taken from the Substance Abuse and Mental Health Services Administration (SAMHSA) announcement on their website located here:
“All practitioners who have a current DEA registration that includes Schedule III authority, may now prescribe buprenorphine for Opioid Use Disorder in their practice if permitted by applicable state law and SAMHSA encourages them to do so. SAMHSA and DEA are actively working on implementation of a separate provision of the Omnibus related to training requirements for DEA registration that becomes effective in June 2023.”
The South Dakota Division of Behavioral Health has information regarding contracted MAT/MOUD providers on avoidopioidsd.com, as well as other resources related to opioid prevention, treatment, and recovery resources. If you are looking for substance use disorder resources related to treatment services funded by the Division of the Behavioral Health, please visit the website at dss.sd.gov/behavioralhealth/services.
If your facility would like to learn more about ways to combat substance use disorder including helpful tools, please contact the SDAHO Team at 605-361-2281.
